Current:Home > InvestUnanimous Supreme Court preserves access to widely used abortion medication -FundPrime
Unanimous Supreme Court preserves access to widely used abortion medication
View
Date:2025-04-13 03:43:04
Live updates: Follow AP’s coverage of the Supreme Court’s decision to preserve access to mifepristone.
WASHINGTON (AP) — The Supreme Court on Thursday unanimously preserved access to a medication that was used in nearly two-thirds of all abortions in the U.S. last year, in the court’s first abortion decision since conservative justices overturned Roe v. Wade two years ago.
The justices ruled that abortion opponents lacked the legal right to sue over the federal Food and Drug Administration’s approval of the medication, mifepristone, and the FDA’s subsequent actions to ease access to it.
The case had threatened to restrict access to mifepristone across the country, including in states where abortion remains legal.
Justice Brett Kavanaugh wrote for the court that “federal courts are the wrong forum for addressing the plaintiffs’ concerns about FDA’s actions.” Kavanaugh was part of the majority to overturn Roe.
The high court is separately considering another abortion case, about whether a federal law on emergency treatment at hospitals overrides state abortion bans in rare emergency cases in which a pregnant patient’s health is at serious risk.
More than 6 million people have used mifepristone since 2000. Mifepristone blocks the hormone progesterone and primes the uterus to respond to the contraction-causing effect of a second drug, misoprostol. The two-drug regimen has been used to end a pregnancy through 10 weeks gestation.
Health care providers have said that if mifepristone is no longer available or is too hard to obtain, they would switch to using only misoprostol, which is somewhat less effective in ending pregnancies.
President Joe Biden’s administration and drug manufacturers had warned that siding with abortion opponents in this case could undermine the FDA’s drug approval process beyond the abortion context by inviting judges to second-guess the agency’s scientific judgments. The Democratic administration and New York-based Danco Laboratories, which makes mifepristone, argued that the drug is among the safest the FDA has ever approved.
The decision “safeguards access to a drug that has decades of safe and effective use,” Danco spokeswoman Abigail Long said in a statement.
The abortion opponents argued in court papers that the FDA’s decisions in 2016 and 2021 to relax restrictions on getting the drug were unreasonable and “jeopardize women’s health across the nation.”
Kavanaugh acknowledged what he described as the opponents’ “sincere legal, moral, ideological, and policy objections to elective abortion and to FDA’s relaxed regulation of mifepristone.”
But he said they went to the wrong forum and should instead direct their energies to persuading lawmakers and regulators to make changes.
Those comments pointed to the stakes of the 2024 election and the possibility that an FDA commissioner appointed by Republican Donald Trump, if he wins the White House, could consider tightening access to mifepristone.
The mifepristone case began five months after the Supreme Court overturned Roe. Abortion opponents initially won a sweeping ruling nearly a year ago from U.S. District Judge Matthew Kacsmaryk, a Trump nominee in Texas, which would have revoked the drug’s approval entirely. The 5th U.S. Circuit Court of Appeals left intact the FDA’s initial approval of mifepristone. But it would reverse changes regulators made in 2016 and 2021 that eased some conditions for administering the drug.
The Supreme Court put the appeals court’s modified ruling on hold, then agreed to hear the case, though Justices Samuel Alito, the author of the decision overturning Roe, and Clarence Thomas would have allowed some restrictions to take effect while the case proceeded.
___
Follow the AP’s coverage of the U.S. Supreme Court at https://apnews.com/hub/us-supreme-court.
veryGood! (2)
Related
- South Korea's acting president moves to reassure allies, calm markets after Yoon impeachment
- Transcript: Utah Gov. Spencer Cox on Face the Nation, July 9, 2023
- Union wins made big news this year. Here are 5 reasons why it's not the full story
- Southwest cancels another 4,800 flights as its reduced schedule continues
- Sonya Massey's father decries possible release of former deputy charged with her death
- Russia's economy is still working but sanctions are starting to have an effect
- Activists Call for Delay to UN Climate Summit, Blaming UK for Vaccine Delays
- Trump’s New Clean Water Act Rules Could Affect Embattled Natural Gas Projects on Both Coasts
- EU countries double down on a halt to Syrian asylum claims but will not yet send people back
- Q&A: An Environmental Justice Champion’s Journey From Rural Alabama to Biden’s Climate Task Force
Ranking
- The White House is cracking down on overdraft fees
- You'll Whoop It up Over This Real Housewives of Orange County Gift Guide
- In defense of gift giving
- Southwest plans on near-normal operations Friday after widespread cancellations
- 'Malcolm in the Middle’ to return with new episodes featuring Frankie Muniz
- Facebook parent Meta will pay $725M to settle a privacy suit over Cambridge Analytica
- Tennessee ban on transgender care for minors can be enforced, court says
- How an 11-year-old Iowa superfan got to meet her pop idol, Michael McDonald
Recommendation
Elon Musk's skyrocketing net worth: He's the first person with over $400 billion
Fortnite maker Epic Games agrees to settle privacy and deception cases
Farmworkers brace for more time in the shadows after latest effort fails in Congress
Cultivated meat: Lab-grown meat without killing animals
The Super Bowl could end in a 'three
Every Time We Applauded North West's Sass
John Mellencamp Admits He Was a S--tty Boyfriend to Meg Ryan Nearly 4 Years After Breakup
Republicans plan more attacks on ESG. Investors still plan to focus on climate risk